Orinase-Met 2/500mg Tablets – Dual Diabetes Control Tab

Drug Class: Sulphonylurea + Biguanide Combination | Form: Oral Tablet | Prescription Status: Prescription Only (Rx) — DRAP Registered

What is Orinase-Met 2/500mg Tablet?

Orinase-Met 2/500mg is a fixed-dose dual combination tablet containing Glimepiride 2mg and Metformin Hydrochloride 500mg — a sulphonylurea and a biguanide working through two completely different and complementary mechanisms to control blood sugar more effectively than either medicine alone. Glimepiride directly stimulates the pancreas to release more insulin — providing immediate blood sugar lowering particularly after meals — while Metformin reduces the amount of glucose the liver produces and releases into the bloodstream and improves the sensitivity of muscle cells to insulin. Together they address both insufficient insulin secretion and insulin resistance — the two core defects underlying Type 2 Diabetes (ذیابیطس ٹائپ 2) — providing more complete 24-hour blood sugar control than single-agent therapy. Orinase-Met 2/500mg is used alongside diet and exercise and must always be taken under medical supervision with regular blood sugar and kidney function monitoring.

What is Orinase-Met 2/500mg Used For?

• Type 2 Diabetes Mellitus — improving blood sugar control in adults when diet, exercise, and single-agent therapy are not sufficient (ذیابیطس ٹائپ 2 میں شوگر کا کنٹرول)
• Dual oral antidiabetic therapy — as a convenient single tablet replacing separately taken Glimepiride and Metformin for improved adherence
• Insulin secretion deficiency — Glimepiride component addresses inadequate pancreatic insulin release
• Insulin resistance — Metformin component addresses peripheral and hepatic insulin resistance
• It is not used for Type 1 Diabetes, diabetic ketoacidosis, or in patients with complete pancreatic beta-cell failure

How Does Orinase-Met 2/500mg Work?

Glimepiride 2mg — Third-Generation Sulphonylurea: Glimepiride belongs to the sulphonylurea class of antidiabetic medicines — it works by binding to specific sulphonylurea receptors (SUR1) on pancreatic beta cells, closing ATP-sensitive potassium channels. This closure causes membrane depolarisation — triggering the opening of voltage-gated calcium channels and the influx of calcium ions into the beta cell. The resulting rise in intracellular calcium stimulates the exocytosis of insulin-containing secretory granules — increasing insulin release into the bloodstream independently of blood glucose levels. Glimepiride also has extrapancreatic effects — improving insulin sensitivity in peripheral tissues by increasing glucose transporter (GLUT4) activity in muscle and fat cells. Being a third-generation sulphonylurea, Glimepiride has a lower risk of severe hypoglycaemia than older sulphonylureas like Glibenclamide — due to its more selective receptor binding and shorter duration of action relative to some other members of the class.

Metformin HCl 500mg — Biguanide: Metformin works primarily in the liver — activating AMP-activated protein kinase (AMPK) which reduces hepatic gluconeogenesis (the liver's production of new glucose) and glycogenolysis (the breakdown of stored glycogen into glucose). This reduces the liver's contribution of excess glucose to the bloodstream — particularly the elevated fasting glucose that characterises Type 2 Diabetes. Metformin also improves the sensitivity of peripheral muscle cells to insulin — enhancing glucose uptake and utilisation — and mildly slows intestinal glucose absorption. Crucially, Metformin does not stimulate insulin secretion — meaning it does not cause hypoglycaemia when used alone — and is generally weight-neutral or causes modest weight loss, making it a cornerstone of Type 2 Diabetes management.

Combined Dual Effect: Glimepiride addresses inadequate insulin secretion from the pancreas while Metformin reduces excessive glucose production from the liver and improves peripheral insulin utilisation — two separate pathways of blood sugar dysregulation addressed simultaneously. This complementary dual action produces significantly better HbA1c reduction and fasting and post-meal glucose control than either medicine alone.

Dosage and Administration

⚠️ Always take exactly as prescribed by your doctor. Never adjust the dose without medical advice. Always take with food — particularly important for the Glimepiride component to reduce hypoglycaemia risk.

Critical Dosing Rules:

• Always take with food — taking on an empty stomach significantly increases the risk of hypoglycaemia (low blood sugar / شوگر کا گرنا) from the Glimepiride component
• Kidney function (creatinine and eGFR) must be checked before starting and monitored regularly — Metformin is unsafe in significant kidney impairment and must be stopped if eGFR falls below 45 mL/min
• Monitor blood sugar regularly — particularly during dose changes, illness, unusual physical activity, or dietary changes; hypoglycaemia is more likely with Glimepiride than with Metformin alone
• Metformin must be stopped before iodinated contrast dye procedures (CT scans) and restarted only after kidney function is confirmed normal — minimum 48 hours after the procedure
• Temporarily stop Orinase-Met during serious illness, surgery, or prolonged fasting — both components carry specific risks during these situations
• Dose adjustment required in elderly patients — more sensitive to hypoglycaemia from Glimepiride and to Metformin accumulation from age-related kidney function decline

How to Take:

• Swallow the tablet whole with a full glass of water
• Always take with food or immediately at the start of a meal — reduces stomach upset from Metformin and hypoglycaemia risk from Glimepiride
• Take at the same time each day — consistent dosing maintains stable blood sugar control throughout the day
• If a dose is missed, take it as soon as remembered with the next meal — skip if it is nearly time for the next dose; never double the dose

Active Ingredients

Who Should NOT Take Orinase-Met 2/500mg?

Do not take if you:

• Are allergic to Glimepiride, any sulphonylurea, Metformin, or any ingredient in the tablet
• Have Type 1 Diabetes or diabetic ketoacidosis
• Have moderate to severe kidney disease (eGFR below 45 mL/min)
• Have severe liver disease
• Have severe heart failure or respiratory failure — lactic acidosis risk with Metformin
• Drink excessive alcohol regularly — increases both hypoglycaemia and lactic acidosis risk
• Are having surgery requiring general anaesthesia — temporarily stop beforehand
• Are under 18 years of age
• Are pregnant — Glimepiride is contraindicated in pregnancy; insulin is the preferred antidiabetic in pregnancy

Always consult your doctor before taking Orinase-Met if you have:

• Mild kidney impairment (گردے کی بیماری) — close monitoring and possible dose adjustment required
• Liver disease (جگر کی بیماری) — Glimepiride is metabolised in the liver; use with caution
• G6PD deficiency — sulphonylureas can cause haemolytic anaemia in this condition
• Adrenal or pituitary insufficiency — increased hypoglycaemia sensitivity
• History of hypoglycaemia unawareness — particularly dangerous with Glimepiride
• Are elderly — significantly higher hypoglycaemia risk from Glimepiride and Metformin accumulation risk
• Are breastfeeding — both components pass into breast milk
• Are taking beta-blockers — mask the warning signs of hypoglycaemia
• Are on other antidiabetic medicines, NSAIDs, or fluoroquinolone antibiotics — hypoglycaemia risk increases

Side Effects

Common Side Effects:

• Hypoglycaemia (low blood sugar) — most clinically important side effect of Glimepiride; symptoms include shaking, sweating, palpitations, confusion, dizziness, and extreme hunger (شوگر کا گرنا) — treat immediately with glucose or sugar
• Nausea or stomach discomfort — Metformin related; significantly reduced by always taking with food
• Diarrhoea or loose stools — Metformin related; most common in the first few weeks; usually self-limiting
• Metallic taste in the mouth — Metformin related; usually temporary
• Mild headache — usually temporary
• Weight gain — Glimepiride-related insulin stimulation promotes modest weight gain; less pronounced than older sulphonylureas
• Mild skin rash or itching — sulphonylurea class effect; usually mild and temporary

Serious Side Effects — Stop Taking and Seek Medical Help Immediately:

• Severe hypoglycaemia — loss of consciousness, seizures, or inability to swallow — Glimepiride-induced severe low blood sugar requiring immediate intravenous glucose administration; life-threatening emergency (طبی ہنگامی صورتحال)
• Lactic acidosis — rare but life-threatening Metformin complication; severe muscle pain, difficulty breathing, stomach pain, feeling very cold, dizzy, or confused — seek emergency care immediately
• Severe allergic reaction — swelling of face, lips, tongue or throat, difficulty breathing, widespread rash (یہ طبی ہنگامی صورتحال ہے)
• Severe skin reactions — Stevens-Johnson syndrome, widespread blistering or peeling skin — rare sulphonylurea related reaction; stop immediately
• Haemolytic anaemia — extreme fatigue, pallor, rapid heartbeat, dark urine — rare sulphonylurea reaction; particularly in G6PD deficient patients
• Severe liver toxicity — yellowing of skin or eyes (یرقان), dark urine, extreme fatigue — rare but reported with sulphonylureas; stop immediately
• Severe hyponatraemia (dangerously low sodium) — confusion, seizures, extreme weakness — rare sulphonylurea related syndrome of inappropriate ADH secretion

Drug Interactions

Storage Instructions

• Store below 25°C in a cool, dry place
• Protect from moisture and direct sunlight
• Keep in original blister pack until use
• Keep out of reach of children (بچوں کی پہنچ سے دور رکھیں)
• Do not use after the expiry date printed on the pack

Frequently Asked Questions (FAQs)

Q: What should I do if I experience symptoms of low blood sugar while taking Orinase-Met 2/500mg? If you experience shaking, sweating, dizziness, or confusion — take glucose tablets, sugar, or a sweet drink immediately; if the patient loses consciousness seek emergency medical care immediately as severe Glimepiride-induced hypoglycaemia requires intravenous glucose treatment.

Q: Why must Orinase-Met be stopped before a CT scan with contrast dye? The contrast dye can temporarily reduce kidney function — if Metformin accumulates due to impaired kidney clearance it can cause lactic acidosis, a rare but life-threatening condition; always inform your doctor and radiologist that you are taking Metformin before any imaging procedure involving contrast dye.

Q: Can I take Orinase-Met 2/500mg during Ramadan fasting? Fasting significantly alters meal timing and increases hypoglycaemia risk from Glimepiride — always consult your doctor before Ramadan to review and adjust the timing and dose of your diabetes medicines; never fast without medical guidance when taking sulphonylurea medicines.

Q: Is Orinase-Met 2/500mg safe during pregnancy? No — Glimepiride is contraindicated during pregnancy as it crosses the placenta and can cause dangerous neonatal hypoglycaemia; insulin is the preferred and safest antidiabetic medicine during pregnancy; inform your doctor immediately if you become or plan to become pregnant while taking this medicine.

Medical Disclaimer: This information is for general awareness only and does not replace advice from your doctor or pharmacist. Type 2 Diabetes requires ongoing medical supervision — never adjust or stop your diabetes medication without consulting your healthcare provider. Always carry glucose tablets or sugar with you in case of hypoglycaemia while taking Glimepiride-containing medicines.